Ftse Mib
34.603,61
-0,64%
DAX
18.726,76
-0,21%
S&P 500
5.321,41
0,25%
NASDAQ
16.832,62
0,22%
Bitcoin
70.079,77
-0,07%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ AzurRx BioPharma Inc (AZRX) AzurRx BioPharma Inc (AZRX) Notizie

AZRX

AzurRx BioPharma (AZRX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:AZRX
DataOraFonteTitoloSimboloCompagnia
27/06/202323:04Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:AZRXAzurRx BioPharma Inc
23/06/202322:06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AZRXAzurRx BioPharma Inc
20/06/202322:26Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:AZRXAzurRx BioPharma Inc
05/06/202313:01Edgar (US Regulatory)Securities Registration Statement (s-1)NASDAQ:AZRXAzurRx BioPharma Inc
15/05/202323:21Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:AZRXAzurRx BioPharma Inc
12/05/202314:33Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:AZRXAzurRx BioPharma Inc
05/04/202322:18Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:AZRXAzurRx BioPharma Inc
04/04/202323:29Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:AZRXAzurRx BioPharma Inc
28/03/202312:05Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:AZRXAzurRx BioPharma Inc
23/03/202322:00Edgar (US Regulatory)Small Company Offering and Sale of Securities Without Registration (d)NASDAQ:AZRXAzurRx BioPharma Inc
20/03/202321:11Edgar (US Regulatory)Annual Report (10-k)NASDAQ:AZRXAzurRx BioPharma Inc
09/01/202315:23Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:AZRXAzurRx BioPharma Inc
07/12/202222:17Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:AZRXAzurRx BioPharma Inc
29/11/202200:42Edgar (US Regulatory)Securities Registration (section 12(g)) (8-a12g)NASDAQ:AZRXAzurRx BioPharma Inc
11/10/202214:13Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(4) (424b4)NASDAQ:AZRXAzurRx BioPharma Inc
22/09/202214:56Edgar (US Regulatory)Securities Registration Statement (s-1/a)NASDAQ:AZRXAzurRx BioPharma Inc
25/07/202223:28Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:AZRXAzurRx BioPharma Inc
15/07/202222:42Edgar (US Regulatory)Proxy Soliciting Materials (revised) (prer14a)NASDAQ:AZRXAzurRx BioPharma Inc
17/05/202222:35Edgar (US Regulatory)Notification That Quarterly Report Will Be Submitted Late (nt 10-q)NASDAQ:AZRXAzurRx BioPharma Inc
03/03/202200:02Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:AZRXAzurRx BioPharma Inc
02/03/202200:16Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:AZRXAzurRx BioPharma Inc
21/09/202118:47GlobeNewswire Inc.AzurRx BioPharma to Change Corporate Name to First Wave BioPharma TodayNASDAQ:AZRXAzurRx BioPharma Inc
14/09/202113:30GlobeNewswire Inc.AzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave Bio and Creation of First Wave BioPharmaNASDAQ:AZRXAzurRx BioPharma Inc
13/09/202112:00GlobeNewswire Inc.AzurRx BioPharma Announces Acquisition of First Wave Bio and its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease IndicationsNASDAQ:AZRXAzurRx BioPharma Inc
10/09/202118:45GlobeNewswire Inc.AzurRx BioPharma Announces Reverse Stock SplitNASDAQ:AZRXAzurRx BioPharma Inc
10/09/202114:30GlobeNewswire Inc.AzurRx BioPharma Activates New Clinical Trial Sites in India for Phase 2 RESERVOIR Trial Evaluating Niclosamide for the Treatment of COVID-19 Gastrointestinal InfectionsNASDAQ:AZRXAzurRx BioPharma Inc
09/09/202114:30GlobeNewswire Inc.AzurRx BioPharma Announces Positive Results from Independent Data Monitoring Committee Review of Safety Data from Part 1 of RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal InfectionsNASDAQ:AZRXAzurRx BioPharma Inc
07/09/202122:30GlobeNewswire Inc.AzurRx BioPharma to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment ConferenceNASDAQ:AZRXAzurRx BioPharma Inc
18/08/202113:05GlobeNewswire Inc.AzurRx BioPharma Announces Positive Topline Data For Phase 2 MS1819 Combination Therapy Trial in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency (EPI)NASDAQ:AZRXAzurRx BioPharma Inc
17/08/202113:00GlobeNewswire Inc.AzurRx BioPharma Announces WHO Publication of “Adrulipase Alfa” as International Nonproprietary Name for MS1819NASDAQ:AZRXAzurRx BioPharma Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:AZRX

La tua Cronologia

USOTC
JVTSF
Juventus Football Club (PK)
ASX
MYGN
AQSE
IBGX.GB
iShares Euro Govt Bond 3...
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network